Christopher Schaber

Soligenix Inc.

Image: Christopher Schaber

Christopher J. Schaber, Ph.D., has more than 25 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been the Soligenix president, chief executive officer and a director since August 2006. He was appointed chairman of the board in 2009. He also serves on the boards of directors of the Biotechnology Council of New Jersey and the Alliance for Biosecurity, and has been a member of the corporate councils of both the National Organization for Rare Diseases and the American Society for Blood and Marrow Transplantation. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as executive vice president and CEO of Discovery Laboratories Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a cofounder of Acute Therapeutics Inc., and served as its vice president of regulatory compliance and drug development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD Inc. as worldwide director of regulatory affairs and operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his bachelor's degree from Western Maryland College, his master's degree in pharmaceutics from Temple University School of Pharmacy and his Ph.D. in pharmaceutical sciences from the Union Graduate School.

Due to permission requirements, not all quotes are shown.